Alterity Therapeutics Ltd's filing for a mixed shelf of up to $50 million indicates that the company may be planning to issue new shares in the future. This could potentially dilute the value of existing shares, leading to a decrease in the stock price. However, the actual impact will depend on the market's perception of the company's growth prospects and the use of the raised funds.